AR104501A1 - ANTI-AP2 ANTIBODIES AND ANTIGEN BINDING AGENTS TO TREAT METABOLIC DISORDERS - Google Patents
ANTI-AP2 ANTIBODIES AND ANTIGEN BINDING AGENTS TO TREAT METABOLIC DISORDERSInfo
- Publication number
- AR104501A1 AR104501A1 ARP160101244A ARP160101244A AR104501A1 AR 104501 A1 AR104501 A1 AR 104501A1 AR P160101244 A ARP160101244 A AR P160101244A AR P160101244 A ARP160101244 A AR P160101244A AR 104501 A1 AR104501 A1 AR 104501A1
- Authority
- AR
- Argentina
- Prior art keywords
- reduced
- antibodies
- cardiovascular disease
- antigen binding
- binding agents
- Prior art date
Links
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Anticuerpos anti-AP2 y agentes de unión al antígeno mejorados, y composiciones de los mismos, dirigidos a la chaperona de lípido aP2/FABP4 (denominado aP2) que son de utilidad en el tratamiento de trastornos tales como diabetes, obesidad, enfermedad cardiovascular, enfermedad de hígado graso y/o cáncer, entre otros. En un aspecto, se divulgan tratamientos mejorados para trastornos mediados por aP2 en donde el blanco es la aP2 en suero y la actividad biológica de aP2 se neutraliza o modula usando anticuerpos monoclonales anti-aP2 de afinidad de unión baja, lo cual proporciona niveles más bajos de glucosa en sangre en ayuno, un metabolismo sistémico de glucosa mejorado, mayor sensibilidad sistémica a la insulina, masa de grasas reducida, esteatosis hepática reducida, enfermedad cardiovascular reducida y/o un riesgo reducido de desarrollar una enfermedad cardiovascular.Improved anti-AP2 antibodies and antigen binding agents, and compositions thereof, directed to the lipid chaperone aP2 / FABP4 (called aP2) that are useful in the treatment of disorders such as diabetes, obesity, cardiovascular disease, disease of fatty liver and / or cancer, among others. In one aspect, improved treatments for aP2-mediated disorders are reported where the target is serum aP2 and the biological activity of aP2 is neutralized or modulated using anti-aP2 monoclonal antibodies of low binding affinity, which provides lower levels. fasting blood glucose, an improved systemic glucose metabolism, increased systemic insulin sensitivity, reduced fat mass, reduced liver steatosis, reduced cardiovascular disease and / or a reduced risk of developing cardiovascular disease.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562155217P | 2015-04-30 | 2015-04-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR104501A1 true AR104501A1 (en) | 2017-07-26 |
Family
ID=59485523
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160101244A AR104501A1 (en) | 2015-04-30 | 2016-05-02 | ANTI-AP2 ANTIBODIES AND ANTIGEN BINDING AGENTS TO TREAT METABOLIC DISORDERS |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR104501A1 (en) |
-
2016
- 2016-05-02 AR ARP160101244A patent/AR104501A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2017012385A2 (en) | Anti-human adipocyte lipid binding protein (ap2) and antigen binding agents | |
| Pockley et al. | Serum heat shock protein 70 levels predict the development of atherosclerosis in subjects with established hypertension | |
| Pasterkamp | Methods of accelerated atherosclerosis in diabetic patients | |
| Chen et al. | Expression of the vitamin d receptor is increased in the hypertrophic heart | |
| ECSP14001260A (en) | BI-SPECIFIC IMMUNOLIGANTS TARGETED AGAINST TNF AND IL-17 CROSS REFERENCE TO RELATED REQUESTS | |
| Pirompol et al. | Supra-physiological dose of testosterone induces pathological cardiac hypertrophy | |
| BR112018070676A2 (en) | multispecific antigen binding constructs that target immunotherapeutic agents | |
| EA201370126A1 (en) | HUMAN ANTIBODIES TO THE GLUCAGON RECEPTOR | |
| PE20141173A1 (en) | COMPOSITIONS AND METHODS FOR TREATMENT IN WIDE-SPECTRUM CLINICAL APPLICATIONS, NON-DIFFERENTIATED OR COMBINED | |
| UY33144A (en) | HUMAN ANTIBODIES FOR HUMAN ANGIOPOYETIN PROTEIN 4 | |
| Hopps et al. | Exercise in obesity management. | |
| BR112013010556A2 (en) | Appropriate methods and compositions for promoting healthy skin | |
| Jäger et al. | Metabolomic analysis of resveratrol-induced effects in the human breast cancer cell lines MCF-7 and MDA-MB-231 | |
| UY30525A1 (en) | DIRECTED UNION AGENTS WHOSE WHITE IS THE PDGFR-ALFA AND ITS USES | |
| Tranchita et al. | The beneficial role of physical exercise on anthracyclines induced cardiotoxicity in breast cancer patients | |
| CL2021000427A1 (en) | Acylated calcitonin mimics | |
| Rennie et al. | Maintenance of the musculoskeletal mass by control of protein turnover: the concept of anabolic resistance and its relevance to the transplant recipient. | |
| Jaakkola et al. | Association of adiponectin with adolescent cardiovascular health in a dietary intervention study | |
| CR20190086A (en) | Antibody or an antigen-binding fragment thereof capable of binding to a human receptor of interleukin-6 | |
| AR104501A1 (en) | ANTI-AP2 ANTIBODIES AND ANTIGEN BINDING AGENTS TO TREAT METABOLIC DISORDERS | |
| Vassalle et al. | New insights for matrix Gla protein, vascular calcification and cardiovascular risk and outcome | |
| Fabie et al. | Anatomic danger of percutaneous section of the inter-metatarsal ligament for the treatment of Morton's neuroma | |
| BR112022004302A2 (en) | Anti-il-27 antibodies and uses thereof | |
| Werner et al. | Metabolic effect and receptor signalling profile of a non-metabolisable insulin glargine analogue | |
| Azuma et al. | Vitamin K insufficiency predicts incidence of frailty in community-dwelling older adults: The Otassha Study |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |